Autism Social Deficits Reversed by Romidepsin Anti-Cancer Drug
Synopsis: Using an epigenetic mechanism, romidepsin restored gene expression and alleviated social deficits in animal models of autism. The research, published in Nature Neuroscience, demonstrated that brief treatment with a very low dose of romidepsin, a Food and Drug Administration-approved anti-cancer drug, restored social deficits in animal models of autism in a sustained fashion. The extensive overlap in risk genes for autism and cancer, many of which are chromatin remodeling factors, supports the idea of repurposing epigenetic drugs used in cancer treatment as targeted treatments for autism.
Of all the challenges that come with a diagnosis of Autism Spectrum Disorder (ASD), the social difficulties are among the most devastating. Currently, there is no treatment for this primary symptom of ASD. New research at the University at Buffalo reveals the first evidence that it may be possible to use a single compound to alleviate the behavioral symptoms by targeting sets of genes involved in the disease.
The research, published in Nature Neuroscience, demonstrated that brief treatment with a very low dose of romidepsin, a Food and Drug Administration-approved anti-cancer drug, restored social deficits in animal models of autism in a sustained fashion.
The three-day treatment reversed social deficits in mice deficient in a gene called Shank 3, an important risk factor for ASD. This effect lasted for three weeks, spanning the juvenile to late adolescent period, a critical developmental stage for social and communication skills. That is equivalent to several years in humans, suggesting the effects of a similar treatment could potentially be long-lasting, the researchers say.
Also known as Istodax, Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, is an anti-cancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin works by blocking enzymes known as histone deacetylases, thus inducing apoptosis. The United States FDA approved romidepsin for CTCL in November 2009 and approved romidepsin for other peripheral T-cell lymphomas (PTCLs) in June 2011.
SH3 and multiple ankyrin repeat domains 3 (Shank3), also known as proline-rich synapse-associated protein 2 (ProSAP2) - A protein that in humans is encoded by the SHANK3 gene on chromosome 22. The SHANK3 gene provides instructions for making a protein that is found in many of the body's tissues but is most abundant in the brain. Within synapses, the SHANK3 protein acts as a scaffold that supports the connections between neurons, ensuring that the signals sent by one neuron are received by another. Mutations in this gene are associated with autism spectrum disorder (ASD). This gene is often missing in patients with 22q13.3 deletion syndrome, although not in all cases.
Profound, Prolonged Effect
"We have discovered a small molecule compound that shows a profound and prolonged effect on autism-like social deficits without obvious side effects, while many currently used compounds for treating a variety of psychiatric diseases have failed to exhibit the therapeutic efficacy for this core symptom of autism," said Zhen Yan, PhD, professor in the Department of Physiology and Biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB, and senior author on the paper.
The study builds on her previous research from 2015.
That work revealed how the loss of Shank 3 disrupts neuronal communications by affecting the function of the NMDA (n-methyl-D-aspartate) receptor, a critical player in regulating cognition and emotion, leading to deficits in social preference that are common in ASD.
In the new research, the UB scientists found they could reverse those social deficits with a very low dose of romidepsin, which, they found, restores gene expression and function using an epigenetic mechanism, where gene changes are caused by influences other than DNA sequences. Yan noted that human genetics studies have suggested that epigenetic abnormalities likely play a major role in ASD.
To pursue these promising findings, Yan has founded a startup company called ASDDR, which was awarded a Small Business Technology Transfer grant from the National Institutes of Health last summer for more than $770,000.
Epigenetics in ASD
Many of the mutations in ASD, Yan explained, result from chromatin remodeling factors, which are involved in dynamically changing the structure of chromatin, the complex of genetic material in the cell nucleus that condenses into chromosomes.
"The extensive overlap in risk genes for autism and cancer, many of which are chromatin remodeling factors, supports the idea of repurposing epigenetic drugs used in cancer treatment as targeted treatments for autism," said Yan.
She and her colleagues knew that chromatin regulators - which control how genetic material gains access to a cell's transcriptional machinery - were key to treating the social deficits in ASD, but the challenge was to know how to affect key risk factors at once.
"Autism involves the loss of so many genes," Yan explained. "To rescue the social deficits, a compound has to affect a number of genes that are involved in neuronal communication."
To do so, the team turned to a type of chromatin remodeler called histone modifiers.
They modify proteins called histones that help organize genetic material in the nucleus so gene expression can be regulated. Since many genes are altered in autism, the UB scientists knew a histone modifier might be effective.
Loosening Up Chromatin
In particular, they were interested in histone deacetylase (HDAC), a family of histone modifiers that are critically involved in the remodeling of chromatin structure and the transcriptional regulation of targeted genes.
"In the autism model, HDAC2 is abnormally high, which makes the chromatin in the nucleus very tight, preventing genetic material from accessing the transcriptional machinery it needs to be expressed," said Yan. "Once HDAC2 is upregulated, it diminishes genes that should not be suppressed, and leads to behavioral changes, such as the autism-like social deficits."
But the anti-cancer drug romidepsin, a highly potent HDAC inhibitor, turned down the effects of HDAC2, allowing genes involved in neuronal signaling to be expressed normally.
"The HDAC inhibitor loosens up the densely packed chromatin so that the transcriptional machinery gains access to the promoter area of the genes; thus they can be expressed," Yan said.
The rescue effect on gene expression was widespread.
When Yan and her co-authors conducted genome-wide screening at the Genomics and Bioinformatics Core at UB's New York State Center of Excellence in Bioinformatics and Life Sciences, they found that romidepsin restored the majority of the more than 200 genes that were suppressed in the autism animal model they used.
"The advantage of being able to adjust a set of genes identified as key autism risk factors may explain the strong and long-lasting efficacy of this therapeutic agent for autism." Yan explained.
She and her colleagues will continue their focus on discovering and developing better therapeutic agents for autism.
Co-authors are Luye Qin, PhD, research assistant professor; Kaijie Ma, research scientist; Zi-Jun Wang, PhD; postdoctoral fellow, Emmanuel Matas, PhD; and Jing Wei, PhD, former postdoctoral fellows, all in Yan's laboratory at the Department of Physiology and Biophysics, and Zihua Hu, PhD, bioinformatics computational scientist at UB's New York State Center of Excellence in Bioinformatics and Life Sciences. The research was funded by the Nancy Lurie Marks Foundation and the NIH.
This quality-reviewed publication pertaining to our Autism Information section was selected for circulation by the editors of Disabled World due to its likely interest to our disability community readers. Though the content may have been edited for style, clarity, or length, the article "Autism Social Deficits Reversed by Romidepsin Anti-Cancer Drug" was originally written by University at Buffalo, and submitted for publishing on 2018/03/12 (Edit Update: 2021/10/30). Should you require further information or clarification, University at Buffalo can be contacted at buffalo.edu. Disabled World makes no warranties or representations in connection therewith.
📢 Discover Related Topics
👍 Share This Information To:
𝕏.com Facebook Reddit
Page Information, Citing and Disclaimer
Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.
Permalink: <a href="https://www.disabled-world.com/health/neurology/autism/romidepsin.php">Autism Social Deficits Reversed by Romidepsin Anti-Cancer Drug</a>
Cite This Page (APA): University at Buffalo. (2018, March 12). Autism Social Deficits Reversed by Romidepsin Anti-Cancer Drug. Disabled World. Retrieved February 21, 2024 from www.disabled-world.com/health/neurology/autism/romidepsin.php
Disabled World provides general information only. Materials presented are never meant to substitute for qualified professional medical care. Any 3rd party offering or advertising does not constitute an endorsement.